Atlas Trials

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Clinical trial NCT04498689 · UNKNOWN

Trial details

NCT number
NCT04498689
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Pancreatic Cancer
Start date
2019-08-01
Primary completion
2022-12-31
Enrollment
117

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.